Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Irinotecan |
Synonyms | |
Therapy Description |
Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM over exp | stomach cancer | decreased response | Irinotecan | Preclinical - Cell culture | Actionable | In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859). | 27638859 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02004262 | Phase II | Irinotecan Erlotinib Cyclophosphamide Capecitabine + Fluorouracil + Gemcitabine | Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | Completed | USA | CAN | 0 |
NCT01520389 | Phase I | MM-151 Irinotecan | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | Completed | USA | 0 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02138617 | Phase II | Leucovorin Bevacizumab Irinotecan Fluorouracil | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05319730 | Phase Ib/II | Irinotecan Paclitaxel Lenvatinib + MK-4830 + Pembrolizumab Irinotecan + MK-4830 + Pembrolizumab MK-4830 + Paclitaxel + Pembrolizumab | A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment | Recruiting | USA | TUR | NOR | ITA | DEU | CHE | BRA | 7 |
NCT04879368 | Phase III | Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan | RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) | Active, not recruiting | USA | ITA | ESP | DEU | AUT | AUS | 3 |
NCT04697628 | Phase III | Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | ARG | 7 |
NCT03430843 | Phase III | Docetaxel Paclitaxel Tislelizumab Irinotecan | A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 4 |
NCT04943627 | Phase III | Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine | Balstilimab in Patients With Recurrent Cervical Cancer. | Withdrawn | USA | 1 |
NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
NCT03257267 | Phase III | Irinotecan Gemcitabine Vinorelbine Pemetrexed Disodium Cemiplimab Topotecan | Study of REGN2810 in Adults With Cervical Cancer | Completed | USA | POL | ITA | GRC | GBR | ESP | CAN | BRA | BEL | AUS | 4 |
NCT01916447 | Phase I | Bevacizumab Trifluridine-tipiracil hydrochloride Irinotecan | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | Completed | USA | 0 |
NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
NCT00063141 | Phase III | Irinotecan Cetuximab + Irinotecan | Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | Completed | USA | SWE | SVK | NOR | NLD | ITA | GBR | FRA | FIN | DEU | CHE | BEL | AUT | AUS | 3 |
NCT00967655 | Phase II | Capecitabine + Panitumumab Irinotecan | Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer | Unknown status | USA | 0 |
NCT02579226 | Phase I | Irinotecan AZD2811 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT02423954 | Phase Ib/II | Temsirolimus Nivolumab Capecitabine Irinotecan | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | Terminated | USA | 0 |
NCT00940316 | Phase II | Irinotecan Erlotinib + Panitumumab | Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | Completed | USA | 0 |
NCT06528496 | Phase II | Irinotecan Doxorubicin Ifosfamide Sargramostim Etoposide Temozolomide Carboplatin Naxitamab Vincristine Sulfate Topotecan Cyclophosphamide | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Recruiting | USA | 0 |
NCT06356311 | Phase III | Trifluridine-tipiracil hydrochloride Irinotecan Paclitaxel Docetaxel SKB264 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Recruiting | USA | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 9 |
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02620423 | Phase I | Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab | Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT02567435 | Phase III | Cyclophosphamide + Dactinomycin + Vincristine Sulfate Temsirolimus Irinotecan | Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
NCT00730158 | Phase II | Irinotecan YIV-906 | A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01347866 | Phase I | Gedatolisib PD-0325901 Irinotecan | Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer | Terminated | USA | ITA | ESP | CAN | 0 |
NCT02625623 | Phase III | Avelumab Paclitaxel Irinotecan | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | Completed | USA | POL | ITA | FRA | ESP | DEU | CZE | BEL | AUS | 1 |
NCT06346392 | Phase III | Rivoceranib Trifluridine-tipiracil hydrochloride Paclitaxel + Ramucirumab Docetaxel Paclitaxel Irinotecan AZD0901 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CHE | CAN | 8 |
NCT06459180 | Phase III | Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan SKB264 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FRA | FIN | ESP | DNK | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 7 |